With its highest honor, a Gold level award, Best in Biz recognizes Jeff Aronin for his lifelong commitment to developing breakthrough therapies for severe medical conditions.

December 3, 2018Paragon Biosciences Chairman and CEO Jeff Aronin was named 2018’s Innovator of the Year, by Best in Biz Awards, for his lifelong commitment to developing medicines for severe diseases. The award highlights Mr. Aronin’s innovations over a 25-year career and Paragon Biosciences’ success, under Mr. Aronin’s leadership, at advancing venture innovation for biopharmaceutical development.

Driven by Jeff Aronin’s vision, Paragon Biosciences’ approach involves identifying unmet patient needs, investing in the development of novel medicines, and incubating biopharmaceutical companies that work toward treatments for people with complex or rare medical conditions.

The Innovator of the Year recognition by Best in Biz was awarded to Mr. Aronin at the Gold level, the organization’s highest honor. The Best in Biz Awards are determined through the scoring of independent judging panels comprised of industry analysts and prominent editors and reporters at respected business, consumer, technology and trade publications. The 2018 judging panel included, among others, writers from Associated Press, Barron’s, Consumer Affairs, Forbes, Healthcare Innovation News, Investment Advisor Magazine, MediaPost, New York Post, New York Times, and Wired.

This Best in Biz Award is one of the many recognitions that Jeff Aronin has received for his approach to biopharmaceutical venture innovation. Insights Care magazine recently recognized Mr. Aronin as one of the most influential leaders in healthcare for his extraordinary track record at improving the quality of life of patients with severe diseases, by developing breakthrough medicines to treat those conditions.

“When we find an opportunity for life-changing care, Paragon forms and incubates companies to develop those therapies,” said Mr. Aronin.

In the past year, Paragon Biosciences’ portfolio companies have invested and committed $454 million to the development of potential new medicines. In 2017, the initial equity raise for Paragon’s most recently-launched portfolio company was the largest private equity financing of a privately-held North American biopharma company that year. It was also among the top 10 venture-capital raises in the history of U.S. biotech firms.

“Winning the 2018 Gold Award for Innovator of the Year is a testament to the hard work and commitment of my team at Paragon – and our vision for how to bring breakthrough therapies to patients,” said Mr. Aronin. “Paragon Biosciences is focused on solving for the critical medical needs that others won’t or can’t address. This recognition from Best in Biz helps build awareness of our collective mission to bring novel treatments and therapies to the patients who need them most.”

About Paragon Biosciences, LLC:
For severe and complex diseases, Paragon Biosciences identifies unmet patient needs, invests in novel therapies to treat those medical conditions, launches biopharmaceutical companies to further develop those therapies, and supports these new portfolio companies with early-incubation services. After which, the portfolio companies operate independently as they conduct clinical trials and seek FDA approval of improved treatments. Paragon Biosciences is headquartered in Chicago, Illinois. For more information, visit: ParagonBioSci.com.

About the Best in Biz Awards:
Since 2011, Best in Biz Awards has made its mark as the only independent business awards program judged each year by a who’s who of prominent reporters and editors selected from top-tier publications from North America and around the world. Over the years, Best in Biz Awards judges have ranged from Associated Press to the Wall Street Journal and winners have spanned the spectrum, from blue-chip companies that form the bedrock of the world economy to some of the most innovative start-ups. For more information, visit: BestInBizAwards.com.

Paragon Biosciences Announces $71.8 Million in New Investment for Portfolio Company Castle Creek Pharma
Paragon Biosciences Names James Robinson President and Chief Operating Officer